Nihon Medi-physics Co., Ltd.

This early-stage study tested a new imaging agent called NMK89 in patients with a specific type of pancreatic cancer. The main goal was to check if the agent is safe and to see how it travels and collects in the body using PET/CT scans. The study involved 10 patients to gather in…